HER2-Expressing Solid Tumors
3 clinical trials · Condition
◉ Watch HER2-Expressing Solid Tumors
| Record | Firm | Date |
|---|---|---|
| Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors (NCT07334119) | Myeloid Therapeutics | 2025-11-25 |
| Gene Therapy for HER-Positive Cancer (SENTRY-HER2) (NCT07192432) | Vironexis Biotherapeutics Inc. | 2025-11-18 |
| Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors (NCT02386501) | Advaxis, Inc. | 2015-09-01 |
Track HER2-Expressing Solid Tumors automatically
Every clearance here is in the API, with alerts when new ones post.